HETEROARYL SUBSTITUTED PYRIDINES AND METHODS OF USE
申请人:AbbVie S.à.r.l.
公开号:US20170349576A1
公开(公告)日:2017-12-07
The invention discloses compounds of Formula I,
wherein X
1
, X
2
, R
1
, and R
2
are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
The invention relates to a method for producing compounds of general formula (I) wherein R
1
is selected from the following groups: (a) OR
5
and (b) mono-, di-, or tri-substituted phenyl; and R
2
represents a group (C
1
-C
6
) alkyl. The method is characterized in that it comprises the following steps: a) reacting a compound of general formula (II) with an acid of general formula R
1
CH
2
COOH (III) in a water-free medium; b) reacting the resulting compound with a strong base in an aprotic solvent in order to obtain an intermediate cyclic compound which forms a compound of general formula (I) after dehydration; and c) isolating said resulting compound of general formula (I).
PYRROLIDINE DERIVATIVES AS NK2 RECEPTOR ANTAGONISTS
申请人:Bissantz Caterina
公开号:US20090312327A1
公开(公告)日:2009-12-17
The present invention relates to compounds of formula I
wherein R
1
, R
2
, R
3
, Ar and n are as defined herein and pharmaceutically active salts, racemic mixtures, enantiomers, optical isomers or tautomeric forms thereof. The compounds can be used for the treatment of depression, anxiety or schizophrenia.